Hemispherian
The company focuses on developing a novel class of small-molecule drugs that target the TET2 enzyme as an epigenetic therapy for particularly aggressive cancers.
Hemispherian has raised €14M across 3 funding rounds from 5 investors, most recently a Series A round in Nov 2022. Based in Oslo, Norway; active in Healthtech. Data as of 28 Oct 2026.
Oslo, Norwayhemispherian.com ↗
Total raised
€14M
€14,111,240
Funding rounds
3
Investors
5
distinct backers
Active since
2022-05
latest 2022-11
Funding by year
EUR raised per yearHemispherian — funding by year — interactive chart.
Data table
| Hemispherian — funding by year | |
|---|---|
| 2022 | €14M |
Signals
High confidenceRaise-next likelihood7
base rate 44% for Series A
- ▼ Past typical raise window
- ▼ Down/flat last round
- ▼ Low backer re-investment
Exit likelihood10
base rate 11% (2+ rounds)
- ▼ No recent equity round (debt-only or quiet)
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
3 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-11-24 | Series A | €2.8M | Kistefos,Kvantia,Meneldor,Steven Powell | View deal → |
| 2022-10-19 | Other | €10M | European Innovation Council (EIC) | View deal → |
| 2022-05-03 | Seed | €1.3M | Meneldor | View deal → |
Related news
- Hemispherian Raises USD$2.9M in First Tranche of Series A Fundingfinsmes.com · 2022-11
- Hemispherian Raises EUR10M in Financingfinsmes.com · 2022-10
- Norwegian innovative preclinical pharmaceutical company raised $1.4M seedarcticstartup.com · 2022-05
Similar companies
same sector or country- Visma€3.0BNorway · Software
- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Adevinta€1.9BNorway · Marketing
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
Global coverage: FundingData